Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neurofunctional Markers of SSRI Treatment Response in PTSD.

Trial Profile

Neurofunctional Markers of SSRI Treatment Response in PTSD.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 03 Jun 2014 Biomarkers information updated
  • 26 Apr 2012 Actual patient number 41 added as reported by ClinicalTrials.gov.
  • 20 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top